

CITATION REPORT

List of articles citing

Pharmacokinetics of the Converting Enzyme Inhibitor
Cilazapril in Normal Volunteers and the Relationship
to Enzyme Inhibition: Development of a Mathematical Model

DOI: 10.1097/00005344-198701000-00006

Journal of Cardiovascular Pharmacology, 1987, 9, 32-38.

Source: <https://exaly.com/paper-pdf/18766020/citation-report.pdf>

Version: 2024-04-19

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
84	Effect on blood pressure and the renin-angiotensin system of repeated doses of the converting enzyme inhibitor CGS 14824A. <i>European Journal of Clinical Pharmacology</i> , 1987 , 31, 643-6	2.8	17
83	Synthesis of [¹⁴ C]hippuryl-L-histidyl-L-leucine. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 1988 , 25, 247-255	1.9	
82	The effects of the long-acting angiotensin-converting enzyme inhibitor cilazapril on casual, exercise, and ambulatory blood pressure. <i>Clinical Pharmacology and Therapeutics</i> , 1988 , 44, 173-8	6.1	20
81	Angiotensin-converting enzyme inhibitors. Relationship between pharmacodynamics and pharmacokinetics. <i>Clinical Pharmacokinetics</i> , 1988 , 15, 295-318	6.2	49
80	Interactions between cilazapril and propranolol in man; plasma drug concentrations, hormone and enzyme responses, haemodynamics, agonist dose-effect curves and baroreceptor reflex. <i>British Journal of Clinical Pharmacology</i> , 1988 , 26, 547-56	3.8	17
79	Pharmacokinetics of single and consecutive doses of cilazapril and its depressor effects in hypertensive patients with renal dysfunction. <i>American Journal of Hypertension</i> , 1988 , 1, 230S-232S	2.3	1
78	Present aspects and future developments with ACE inhibitors. <i>Cardiology</i> , 1989 , 76 Suppl 2, 1-10	1.6	4
77	Pharmacokinetics of an ACE inhibitor, S-9780, in man: evidence of tissue binding. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1989 , 17, 529-50		34
76	Recent advances in pharmaceutical chemistry--angiotensin-converting enzyme inhibitors. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 1989 , 14, 341-54	2.2	2
75	Pharmacokinetics of the angiotensin converting enzyme inhibitor benazepril.HCl (CGS 14 824 A) in healthy volunteers after single and repeated administration. <i>Biopharmaceutics and Drug Disposition</i> , 1989 , 10, 365-76	1.7	30
74	Metabolic considerations in the approach to diabetic hypertensive patients. <i>American Journal of Medicine</i> , 1989 , 87, 34S-38S	2.4	4
73	Clinical pharmacology of cilazapril. <i>American Journal of Medicine</i> , 1989 , 87, 45S-49S	2.4	11
72	Pharmacokinetics of intravenous cilazaprilat in normal volunteers. <i>British Journal of Clinical Pharmacology</i> , 1989 , 27, 873-5	3.8	7
71	The pharmacokinetics and bioavailability of cilazapril in normal man. <i>British Journal of Clinical Pharmacology</i> , 1989 , 27 Suppl 2, 181S-188S	3.8	29
70	Correlation between plasma concentration of cilazapril and haemodynamic and hormonal effects in healthy man. <i>British Journal of Clinical Pharmacology</i> , 1989 , 27 Suppl 2, 189S-197S	3.8	8
69	The pharmacokinetics and dose proportionality of cilazapril. <i>British Journal of Clinical Pharmacology</i> , 1989 , 27 Suppl 2, 199S-204S	3.8	11
68	A pharmacokinetic study of cilazapril in elderly and young volunteers. <i>British Journal of Clinical Pharmacology</i> , 1989 , 27 Suppl 2, 211S-215S	3.8	16

67	The assessment of ACE activity in man following angiotensin I challenges: a comparison of cilazapril, captopril and enalapril. <i>British Journal of Clinical Pharmacology</i> , 1989 , 27 Suppl 2, 217S-223S	3.8	19
66	The pharmacokinetics and angiotensin converting enzyme inhibition dynamics of cilazapril in essential hypertension. <i>British Journal of Clinical Pharmacology</i> , 1989 , 27 Suppl 2, 263S-266S	3.8	10
65	A pharmacokinetic study of cilazapril in patients with congestive heart failure. <i>British Journal of Clinical Pharmacology</i> , 1989 , 27 Suppl 2, 267S-273S	3.8	9
64	Pharmacokinetics of cilazapril in patients with renal failure. <i>British Journal of Clinical Pharmacology</i> , 1989 , 27 Suppl 2, 275S-282S	3.8	18
63	Antihypertensive effects and pharmacokinetics of single and consecutive doses of cilazapril in hypertensive patients with normal or impaired renal function. <i>British Journal of Clinical Pharmacology</i> , 1989 , 27 Suppl 2, 283S-287S	3.8	7
62	Antihypertensive effects of nitrendipine and cilazapril alone, and in combination in hypertensive patients with chronic renal failure. <i>British Journal of Clinical Pharmacology</i> , 1989 , 27 Suppl 2, 289S-296S	3.8	14
61	Pharmacokinetics and effects on renal function following cilazapril and hydrochlorothiazide alone and in combination in healthy subjects and hypertensive patients. <i>British Journal of Clinical Pharmacology</i> , 1989 , 27 Suppl 2, 323S-328S	3.8	14
60	Lisinopril population pharmacokinetics in elderly and renal disease patients with hypertension. <i>British Journal of Clinical Pharmacology</i> , 1989 , 27, 57-65	3.8	16
59	Cilazapril. <i>Cardiovascular Drug Reviews</i> , 1990 , 8, 1-24		14
58	Pharmacokinetics of cilazapril during repeated oral dosing in healthy young volunteers. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 1990 , 15, 63-7	2.7	4
57	Kinetic-dynamic relations and individual responses to enalapril. <i>Hypertension</i> , 1990 , 15, 301-9	8.5	54
56	Angiotensin converting enzyme inhibitors and moderate hypertension. <i>Drugs</i> , 1990 , 40, 326-45	12.1	60
55	Newer ACE inhibitors. A look at the future. <i>Drugs</i> , 1990 , 40, 800-28	12.1	63
54	ACE inhibitors and tissue binding. <i>Lancet, The</i> , 1990 , 336, 718-720	40	6
53	The place of simultaneous pharmacokinetic pharmacodynamic modeling in new drug development: trends and perspectives. <i>Fundamental and Clinical Pharmacology</i> , 1990 , 4 Suppl 2, 103s-115s	3.1	4
52	Pharmacokinetics of perindopril and its metabolites in healthy volunteers. <i>Fundamental and Clinical Pharmacology</i> , 1990 , 4, 175-89	3.1	28
51	Tissue and plasma angiotensin converting enzyme and the response to ACE inhibitor drugs. <i>British Journal of Clinical Pharmacology</i> , 1991 , 31, 1-13	3.8	24
50	Transpulmonary pharmacokinetics of an ACE inhibitor (perindoprilat) in man. <i>British Journal of Clinical Pharmacology</i> , 1991 , 32, 193-9	3.8	1

49	The description and prediction of antihypertensive drug response: an individualised approach. <i>British Journal of Clinical Pharmacology</i> , 1991 , 31, 627-34	3.8	9
48	Clinical pharmacology of cilazapril. <i>Drugs</i> , 1991 , 41 Suppl 1, 3-10	12.1	6
47	Clinical pharmacodynamic studies with cilazapril and a combination of cilazapril and propranolol. <i>Drugs</i> , 1991 , 41 Suppl 1, 11-7	12.1	6
46	Cilazapril. A review. <i>Drugs</i> , 1991 , 41 Suppl 1, 18-24	12.1	28
45	Cilazapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cardiovascular disease. <i>Drugs</i> , 1991 , 41, 799-820	12.1	23
44	The role of enzyme and substrate concentration in the evaluation of serum angiotensin converting enzyme (ACE) inhibition by enalaprilat in vitro. <i>Biochemical Pharmacology</i> , 1991 , 42, 1729-37	6	11
43	Pharmacokinetics and converting enzyme inhibition after morning and evening administration of oral enalapril to healthy subjects. <i>European Journal of Clinical Pharmacology</i> , 1991 , 40, 95-9	2.8	21
42	The disposition of [14C]-labelled benazepril HCl in normal adult volunteers after single and repeated oral dose. <i>Xenobiotica</i> , 1991 , 21, 251-61	2	32
41	Dose responses and pharmacokinetics for the angiotensin converting enzyme inhibitor quinapril. <i>Clinical Pharmacology and Therapeutics</i> , 1992 , 51, 260-5	6.1	15
40	The effect of saturation of ACE binding sites on the pharmacokinetics of enalaprilat in man. <i>British Journal of Clinical Pharmacology</i> , 1992 , 33, 155-60	3.8	1
39	Studies with low dose intravenous diacid ACE inhibitor (perindoprilat) infusions in normotensive male volunteers. <i>British Journal of Clinical Pharmacology</i> , 1992 , 34, 115-21	3.8	8
38	Antihypertensive drugs: individualized analysis and clinical relevance of kinetic-dynamic relationships. 1992 , 53, 67-79		10
37	ACE inhibitors in renal disease. <i>Kidney International</i> , 1992 , 42, 463-79	9.9	57
36	Trandolapril in hypertension: overview of a new angiotensin-converting enzyme inhibitor. <i>American Journal of Cardiology</i> , 1992 , 70, 27D-34D	3	22
35	Lack of correlation between the acute haemodynamic response to intravenous captopril and plasma concentrations of angiotensin II in patients with chronic cardiac failure. <i>European Journal of Clinical Pharmacology</i> , 1992 , 43, 1-5	2.8	3
34	The influence of hydrochlorothiazide on the pharmacokinetics of enalapril in elderly patients. <i>European Journal of Clinical Pharmacology</i> , 1992 , 43, 173-7	2.8	7
33	A mathematical model for dynamics of cardiovascular drug action: application to intravenous dihydropyridines in healthy volunteers. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1993 , 21, 489-514		33
32	Pharmacologic profile of trandolapril, a new angiotensin-converting enzyme inhibitor. <i>American Heart Journal</i> , 1993 , 125, 1525-31	4.9	23

31	A clinical pharmacological assessment of doxazosin and enalapril in combination. <i>British Journal of Clinical Pharmacology</i> , 1993 , 36, 599-602	3.8	2
30	Enalapril clinical pharmacokinetics and pharmacokinetic-pharmacodynamic relationships. An overview. <i>Clinical Pharmacokinetics</i> , 1993 , 25, 274-82	6.2	42
29	Angiotensin-converting enzyme (ACE)-inhibition in cirrhosis. Pharmacokinetics and dynamics of the ACE-inhibitor cilazapril (Ro 31-2848). <i>Journal of Hepatology</i> , 1993 , 17, 40-7	13.4	15
28	Role of neutral endopeptidase and kinase II on substance P-induced increase in nasal obstruction in patients with allergic rhinitis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1994 , 149, 113-7	10.2	15
27	Concentration-effect analysis of antihypertensive drug response. Focus on calcium antagonists. <i>Clinical Pharmacokinetics</i> , 1994 , 26, 472-85	6.2	11
26	Normalization of insulin resistance in non-obese essential hypertension by cilazapril treatment. <i>Clinical and Experimental Hypertension</i> , 1995 , 17, 1257-68	2.2	22
25	Comparison of the pharmacokinetics and pharmacodynamics of oral doses of perindopril in normotensive Chinese and Caucasian volunteers. <i>British Journal of Clinical Pharmacology</i> , 1995 , 39, 361-8	3.8	14
24	A comparison of the pharmacokinetics and pharmacodynamics of cilazapril between Chinese and Caucasian healthy, normotensive volunteers. <i>European Journal of Clinical Pharmacology</i> , 1996 , 50, 57-62	2.8	9
23	Pharmacokinetics and haemodynamic effects of the angiotensin converting enzyme inhibitor cilazapril in hypertensive patients with normal and impaired renal function. <i>British Journal of Clinical Pharmacology</i> , 1996 , 42, 615-20	3.8	1
22	Pharmacokinetic-pharmacodynamic model relating zabciprilat plasma concentrations to brachial and femoral haemodynamic effects in normotensive volunteers. <i>British Journal of Clinical Pharmacology</i> , 1998 , 46, 383-93	3.8	4
21	Single dose and steady state pharmacokinetics and pharmacodynamics of the ACE-inhibitor imidapril in hypertensive patients. <i>British Journal of Clinical Pharmacology</i> , 1998 , 45, 377-80	3.8	17
20	A combined specific target site binding and pharmacokinetic model to explore the non-linear disposition of draflazine. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1999 , 27, 257-81		10
19	Bioavailability of repeated oral administration of MDL 100,240, a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase in healthy volunteers. <i>European Journal of Clinical Pharmacology</i> , 2000 , 55, 749-54	2.8	12
18	Pharmacokinetic-pharmacodynamic model for perindoprilat regional haemodynamic effects in healthy volunteers and in congestive heart failure patients. <i>British Journal of Clinical Pharmacology</i> , 2001 , 52, 25-33	3.8	11
17	Pharmacokinetic/pharmacodynamic modelling of the disposition and effect of benazepril and benazeprilat in cats. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2003 , 26, 213-24	1.4	18
16	The pharmacokinetics of perindoprilat in normal volunteers and patients: influence of age and disease state. <i>European Journal of Pharmaceutical Sciences</i> , 2005 , 26, 104-13	5.1	5
15	Human physiologically based pharmacokinetic model for ACE inhibitors: ramipril and ramiprilat. <i>BMC Clinical Pharmacology</i> , 2006 , 6, 1		20
14	Impact of disease states on the pharmacokinetics and pharmacodynamics of angiotensin-converting enzyme inhibitors. <i>Journal of Clinical Pharmacology</i> , 2006 , 46, 968-80	2.9	8

13	Mixed micellar liquid chromatography methods: modelling quantitative retention-activity relationships of angiotensin converting enzyme inhibitors. <i>Biomedical Chromatography</i> , 2008 , 22, 1243-51	1.7	8
12	Initial and steady state pharmacokinetics of cilazapril in congestive cardiac failure. <i>Journal of Pharmacy and Pharmacology</i> , 1991 , 43, 406-10	4.8	2
11	Population pharmacokinetics of the 11 β hydroxysteroid dehydrogenase type 1 inhibitor ABT-384 in healthy volunteers following single and multiple dose regimens. <i>Biopharmaceutics and Drug Disposition</i> , 2014 , 35, 417-29	1.7	10
10	Small-molecule compounds exhibiting target-mediated drug disposition - A case example of ABT-384. <i>Journal of Clinical Pharmacology</i> , 2015 , 55, 1079-85	2.9	10
9	In vivo Target Residence Time and Kinetic Selectivity: The Association Rate Constant as Determinant. <i>Trends in Pharmacological Sciences</i> , 2016 , 37, 831-842	13.2	75
8	A pharmacokinetic/pharmacodynamic model of ACE inhibition of the renin-angiotensin system for normal and impaired renal function. <i>Computers and Chemical Engineering</i> , 2017 , 104, 311-322	4	5
7	Small-Molecule Compounds Exhibiting Target-Mediated Drug Disposition (TMDD): A Minireview. <i>Journal of Clinical Pharmacology</i> , 2017 , 57, 137-150	2.9	21
6	Concept of Pharmacologic Target-Mediated Drug Disposition in Large-Molecule and Small-Molecule Compounds. <i>Journal of Clinical Pharmacology</i> , 2020 , 60, 149-163	2.9	17
5	Converting Enzyme Inhibitors. <i>Handbook of Experimental Pharmacology</i> , 1990 , 377-481	3.2	21
4	Pharmacokinetic-pharmacodynamic model relating lisinopril plasma concentrations to regional hemodynamic effects in healthy volunteers. <i>Journal of Cardiovascular Pharmacology</i> , 1996 , 28, 470-8	3.1	10
3	Pharmacokinetic-pharmacodynamic model relating spiraprilat plasma concentrations to systemic and regional hemodynamic effects in congestive heart failure. <i>Journal of Cardiovascular Pharmacology</i> , 1997 , 30, 253-60	3.1	5
2	Effects of MDL 100,240, a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase on the vasopressor response to exogenous angiotensin I and angiotensin II challenges in healthy volunteers. <i>Journal of Cardiovascular Pharmacology</i> , 1998 , 31, 408-17	3.1	14
1	Pharmakologie der ACE-Hemmer. <i>Aktuelle Therapieprinzipien in Kardiologie Und Angiologie</i> , 1996 , 57-105		